ReviewFrontiers in clinical diabetes and healthcare2025
Obesity paradox in individuals with type 1 diabetes.
Review in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic health, independent of body mass index, is associated with mortality risk in type 1 diabetes.Journal of diabetes investigation · 2026Article
- Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- The Interaction of Health Behaviors and Cardiovascular Diseases: Investigating Morbidity Risks of Disparities in U.S. Adults.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The obesity paradox describes a counterintuitive phenomenon where overweight or mildly obese individuals with chronic diseases show better survival compared to those with normal weight. While this paradox has been reported in conditions such as heart failure and type 2 diabetes, its presence in type 1 diabetes (T1D) remains uncertain. This mini review summarizes current evidence from large cohort studies and a meta-analysis examining the association between body mass index (BMI) and clinical outcomes in individuals with T1D. Most findings do not support a protective effect of higher BMI; instead, both underweight and obesity are associated with increased risks of cardiovascular events and all-cause mortality. Notably, some evidence suggests that individuals with advanced diabetic nephropathy or chronic kidney disease (CKD) may show the lowest mortality at mildly elevated BMI levels. However, these observations may reflect the limitations of using BMI alone to evaluate obesity. Given that individuals with T1D often have reduced skeletal muscle mass, and that those with advanced diabetic complications or comorbidities such as CKD or cancer may develop cachexia, body composition analysis is essential. Accurate assessment of fat mass, muscle mass, bone mass, and water content is critical for understanding obesity-related risks. Future research should integrate body composition metrics to improve risk stratification in T1D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.